RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Bio-Thera Solutions of Guangzhou has begun dosing rheumatoid arthritis patients in a global Phase III trial of its biosimilar to Genentech’s RoActemra®. Bio-Thera’s BAT1806 is one of four Bio-Thera candidates in Phase III trials. The company is developing a portfolio of innovative and biosimilar molecules for various cancers, autoimmune and cardiovascular diseases. Its BLA for a Humira biosimilar is under review at China’s NMPA.
Source: China Biotoday
